These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 33470860)

  • 1. A perspective on RNA interference-based therapeutics for metabolic liver diseases.
    Alkhouri N; Gawrieh S
    Expert Opin Investig Drugs; 2021 Mar; 30(3):237-244. PubMed ID: 33470860
    [No Abstract]   [Full Text] [Related]  

  • 2. Therapeutic Oligonucleotides Targeting Liver Disease: TTR Amyloidosis.
    Niemietz C; Chandhok G; Schmidt H
    Molecules; 2015 Sep; 20(10):17944-75. PubMed ID: 26437390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RNA Interference as a Therapeutic Strategy for the Treatment of Liver Diseases.
    Gonzalez-Rodriguez A; Valverde AM
    Curr Pharm Des; 2015; 21(31):4574-86. PubMed ID: 26486144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RNAi therapeutics for diseases involving protein aggregation: fazirsiran for alpha-1 antitrypsin deficiency-associated liver disease.
    Strnad P; San Martin J
    Expert Opin Investig Drugs; 2023; 32(7):571-581. PubMed ID: 37470509
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An update on the therapeutic role of RNAi in NAFLD/NASH.
    Dehghan H; Ghasempour A; Sabeti Akbar-Abad M; Khademi Z; Sedighi M; Jamialahmadi T; Sahebkar A
    Prog Mol Biol Transl Sci; 2024; 204():45-67. PubMed ID: 38458743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic disorders affecting the liver and heart: Therapeutic efficacy of miRNA-based therapies?
    La Sala L; Carlini V; Conte C; Macas-Granizo MB; Afzalpour E; Martin-Delgado J; D'Anzeo M; Pedretti RFE; Naselli A; Pontiroli AE; Cappato R
    Pharmacol Res; 2024 Mar; 201():107083. PubMed ID: 38309383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liver as a target for oligonucleotide therapeutics.
    Sehgal A; Vaishnaw A; Fitzgerald K
    J Hepatol; 2013 Dec; 59(6):1354-9. PubMed ID: 23770039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted Delivery of Stk25 Antisense Oligonucleotides to Hepatocytes Protects Mice Against Nonalcoholic Fatty Liver Disease.
    Cansby E; Nuñez-Durán E; Magnusson E; Amrutkar M; Booten SL; Kulkarni NM; Svensson LT; Borén J; Marschall HU; Aghajan M; Mahlapuu M
    Cell Mol Gastroenterol Hepatol; 2019; 7(3):597-618. PubMed ID: 30576769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Diagnosis and therapy of inheritable liver diseases: hemochromatisis, Wilson's disease and alpha-1-antitrypsin deficiency].
    Strassburg ChP
    Praxis (Bern 1994); 2005 Jan; 94(3):73-81. PubMed ID: 15719801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Silence superoxide dismutase 1 (SOD1): a promising therapeutic target for amyotrophic lateral sclerosis (ALS).
    Abati E; Bresolin N; Comi G; Corti S
    Expert Opin Ther Targets; 2020 Apr; 24(4):295-310. PubMed ID: 32125907
    [No Abstract]   [Full Text] [Related]  

  • 11. Inherited metabolic disease of the liver.
    Pietrangelo A
    Curr Opin Gastroenterol; 2009 May; 25(3):209-14. PubMed ID: 19342951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bioconjugated Oligonucleotides: Recent Developments and Therapeutic Applications.
    Benizri S; Gissot A; Martin A; Vialet B; Grinstaff MW; Barthélémy P
    Bioconjug Chem; 2019 Feb; 30(2):366-383. PubMed ID: 30608140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic RNA-silencing oligonucleotides in metabolic diseases.
    Goga A; Stoffel M
    Nat Rev Drug Discov; 2022 Jun; 21(6):417-439. PubMed ID: 35210608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hyaluronan-based delivery of therapeutic oligonucleotides for treatment of human diseases.
    Ossipov DA
    Expert Opin Drug Deliv; 2019 Jun; 16(6):621-637. PubMed ID: 31072142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RNAi-based therapeutic strategies for metabolic disease.
    Czech MP; Aouadi M; Tesz GJ
    Nat Rev Endocrinol; 2011 Apr; 7(8):473-84. PubMed ID: 21502982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the Liver with Nucleic Acid Therapeutics for the Treatment of Systemic Diseases of Liver Origin.
    Gogate A; Belcourt J; Shah M; Wang AZ; Frankel A; Kolmel H; Chalon M; Stephen P; Kolli A; Tawfik SM; Jin J; Bahal R; Rasmussen TP; Manautou JE; Zhong XB
    Pharmacol Rev; 2023 Dec; 76(1):49-89. PubMed ID: 37696583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Inherited disorders of liver metabolism].
    Büttner N; Spangenberg HC
    Ther Umsch; 2011 Apr; 68(4):201-6. PubMed ID: 21452141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral delivery of siRNA and antisense oligonucleotides.
    Akhtar S
    J Drug Target; 2009 Aug; 17(7):491-5. PubMed ID: 19530907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oligonucleotide delivery: a patent review (2010 - 2013).
    Grijalvo S; Aviñó A; Eritja R
    Expert Opin Ther Pat; 2014 Jul; 24(7):801-19. PubMed ID: 24798406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antisense and RNA interference approaches to target validation in pain research.
    Kurreck J
    Curr Opin Drug Discov Devel; 2004 Mar; 7(2):179-87. PubMed ID: 15603251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.